Transgene Management
Management criteria checks 2/4
Transgene's CEO is Alessandro Riva, appointed in Jun 2023, has a tenure of 1.25 years. total yearly compensation is €510.00K, comprised of 68.6% salary and 31.4% bonuses, including company stock and options. directly owns 0.022% of the company’s shares, worth €31.09K. The average tenure of the management team and the board of directors is 1.3 years and 4.7 years respectively.
Key information
Alessandro Riva
Chief executive officer
€510.0k
Total compensation
| CEO salary percentage | 68.6% |
| CEO tenure | 1.3yrs |
| CEO ownership | 0.02% |
| Management average tenure | 1.3yrs |
| Board average tenure | 4.7yrs |
Recent management updates
No updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2023 | €510k | €350k | -€22m |
| Sep 30 2023 | n/a | n/a | -€28m |
| Jun 30 2023 | n/a | n/a | -€33m |
| Mar 31 2023 | n/a | n/a | -€33m |
| Dec 31 2022 | €304k | n/a | -€33m |
Compensation vs Market: Alessandro's total compensation ($USD564.97K) is about average for companies of similar size in the UK market ($USD770.39K).
Compensation vs Earnings: Alessandro's compensation has increased whilst the company is unprofitable.
CEO
Alessandro Riva (63 yo)
1.3yrs
Tenure
€510,000
Compensation
Dr. Alessandro Riva, M.D., serves as Chairman of the Board and Chief Executive Officer of Transgene SA since June 1, 2023. He serves as Independent Non-Executive Director at BeiGene, Ltd. since February 01...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Chairman of the Board | 1.3yrs | €510.00k | 0.022% € 31.1k | |
| Director of Pharmaceutical Operations | 2.7yrs | €178.00k | no data | |
| Chief Financial Officer | less than a year | no data | no data | |
| Executive VP & Chief Scientific Officer | no data | no data | no data | |
| VP, General Counsel & Corporate Secretary | 8.5yrs | no data | no data | |
| Chief Human Resources Officer | less than a year | no data | no data | |
| VP of Medical Affairs & Chief Medical Officer | 8.5yrs | no data | no data | |
| VP & Chief Business Officer | less than a year | no data | no data | |
| VP & Director of Human Resources | no data | no data | no data | |
| Project Leader of Personalized Cancer Vaccines | no data | no data | no data |
1.3yrs
Average Tenure
59yo
Average Age
Experienced Management: TNGP's management team is not considered experienced ( 1.3 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Chairman of the Board | 2.3yrs | €510.00k | 0.022% € 31.1k | |
| Director | 24.7yrs | €34.00k | 0.078% € 109.1k | |
| Honorary Chairman | 4.7yrs | no data | 69.27% € 96.9m | |
| Non-Independent Director | 11.3yrs | no data | no data | |
| Director | 19.8yrs | no data | 0.43% € 598.5k | |
| Independent Director | 2.3yrs | €21.00k | no data | |
| Member of Scientific Advisory Board | 1.5yrs | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 7.3yrs | €53.00k | no data | |
| Independent Director | 1.3yrs | no data | no data | |
| Independent Director | 7.3yrs | €75.00k | no data | |
| Director | 3.7yrs | no data | no data |
4.7yrs
Average Tenure
64yo
Average Age
Experienced Board: TNGP's board of directors are considered experienced (4.7 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/09/14 16:01 |
| End of Day Share Price | 2024/06/18 00:00 |
| Earnings | 2023/12/31 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Transgene SA is covered by 11 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Olga Smolentseva | Bryan Garnier & Co |
| Brandon Folkes | Cantor Fitzgerald & Co. |
| Arsene Guekam | CIC Market Solutions (ESN) |